• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/17/21 3:13:00 PM ET
    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LMNL alert in real time by email
    SC 13G/A 1 lmnla1_21621.htm CONSONANCE CAPITAL MANAGEMENT LP lmnla1_21621.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    LIMINAL BIOSCIENCES INC
    (Name of Issuer)
    Common stock, no par value per share
    (Title of Class of Securities)
    53272L103
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 53272L103
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: 53272L103
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Opportunity Fund Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: 53272L103
           
    1
    NAME OF REPORTING PERSON
    Mitchell Blutt
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    HC, IN
    CUSIP No.: 53272L103
           
    1
    NAME OF REPORTING PERSON
    Consonance Capman GP LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    HC, OO
    CUSIP No.: 53272L103
    ITEM 1(a). NAME OF ISSUER:
    LIMINAL BIOSCIENCES INC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    440 Armand-Frappier Boulevard, Suite 300
    Laval, Qubec
    H7V 4B4
    ITEM 2(a). NAME OF PERSON FILING:
    Consonance Capital Management LP
    Consonance Capital Opportunity Fund Management LP
    Mitchell Blutt
    Consonance Capman GP LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    1370 Avenue of the Americas
    Floor 33
    New York, NY 10019
    ITEM 2(c). CITIZENSHIP:
    Consonance Capital Management LP - Delaware USA
    Consonance Capital Opportunity Fund Management LP - Delaware USA
    Mitchell Blutt - USA
    Consonance Capman GP LLC - Delaware USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common stock, no par value per share
    ITEM 2(e). CUSIP NUMBER:
    53272L103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    Consonance Capital Management LP - 0
    Consonance Capital Opportunity Fund Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0
    (b) Percent of class:
    Consonance Capital Management LP - 0%
    Consonance Capital Opportunity Fund Management LP - 0%
    Mitchell Blutt - 0%
    Consonance Capman GP LLC - 0%

    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    (ii) shared power to vote or to direct the vote:
    Consonance Capital Management LP - 0
    Consonance Capital Opportunity Fund Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0
    (iii) sole power to dispose or direct the disposition of:
    (iv) shared power to dispose or to direct the disposition of:
    Consonance Capital Management LP - 0
    Consonance Capital Opportunity Fund Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    The ownership information in Item 4 is incorporated herein by reference.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 53272L103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 16 2021
    Consonance Capital Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Consonance Capital Opportunity Fund Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Mitchell Blutt
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 16 2021
    Consonance Capman GP LLC
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: 53272L103
    Item 4. Ownership:

    This amendment is submitted to report that as of December 31, 2020, none of Consonance Capital Master Account LP (Consonance Master), Consonance Capital Management LP (the investment adviser of Consonance Master, the Adviser), a managed account managed by Consonance Capital Opportunity Fund Management LP (Consonance Opportunity), Consonance Capman GP LLC (Capman), the general partner of the Adviser and Consonance Opportunity, and Mitchell Blutt, the Manager & Member of Capman and Chief Executive Officer of the Adviser, held any shares of the Issuers Common Stock.

    EXHIBIT 99.1
    JOINT FILING AGREEMENT

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G, dated February 16, 2021 (including amendments thereto) with respect to the Common Shares, no par value per share of LIMINAL BIOSCIENCES INC. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

    CONSONANCE CAPITAL MANAGEMENT LP
    By: Consonance Capman GP LLC /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    CONSONANCE CAPITAL OPPORTUNITY FUND MANAGEMENT LP
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    MITCHELL BLUTT
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt

    CONSONANCE CAPMAN GP LLC
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    Get the next $LMNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMNL

    DatePrice TargetRatingAnalyst
    6/24/2021Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $LMNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

      LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the "Arrangement"). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Min

      9/26/23 8:00:00 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

      LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price o

      9/19/23 4:22:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

      LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement"). Further

      9/15/23 11:29:00 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Liminal BioSciences Inc.

      15-12G - Liminal BioSciences Inc. (0001351172) (Filer)

      10/6/23 8:30:57 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liminal BioSciences Inc.

      EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)

      9/27/23 12:15:18 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liminal BioSciences Inc.

      EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)

      9/27/23 12:15:20 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

      SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)

      9/27/23 4:05:14 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

      SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)

      7/12/23 7:09:48 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Liminal BioSciences Inc. (Amendment)

      SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)

      4/5/23 7:30:30 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Liminal BioSciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Liminal BioSciences from Buy to Neutral

      6/24/21 7:18:08 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal Biosciences downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Liminal Biosciences from Overweight to Neutral and set a new price target of $4.50 from $22.00 previously

      6/2/21 6:25:42 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright initiated coverage on Liminal BioSciences with a new price target

      HC Wainwright initiated coverage of Liminal BioSciences with a rating of Buy and set a new price target of $11.00

      2/25/21 10:46:46 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Financials

    Live finance-specific insights

    See more
    • Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

      LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back.

      3/13/23 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

      LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and 647-484-0474, using the following passcode: 722285. An audio replay of the call will be available as of Thursday November

      11/8/22 7:00:00 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

      $55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the second quarter ended June 30, 2022. Liminal BioSciences will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday August 10, 2022. The telephone numbers to access the conference call are 888-390-0620 and 416-764-8651. An a

      8/9/22 5:07:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    Leadership Updates

    Live Leadership Updates

    See more
    • Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

      LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 5, 2023. A total of 2,235,519 common shares were voted, representing 72.02% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Against  Votes % Votes % Si

      6/5/23 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

      CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40 agonist for the treatment of type 2 diabetes Closed December 31, 2022 with just over CAD 37 million cash on hand, expecting to provide cash runway into early 2024Net loss from continuing operations of CAD 6.6 million during the quarter ended December 31, 2022 compared to CAD 8.8 million during the fourth quarter of 2021Regained compliance with minimum bid price requirement for continued listing on the Nasdaq Capital MarketCompleted the sale of a non-core real estate asset at

      3/15/23 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

      $40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023Possibilities to sell non-core assets to further extend runway into 2024Changes to strengthen executive leadership teamLAVAL, QC and CAMBRIDGE, England, Nov. 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today

      11/9/22 4:05:00 PM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care